Proven effective to lower A1C with multiple dosing approaches, including FullSTEP®, a patient-led titration study.3,4
NovoLog® is the #1 selling rapid-acting insulin, and puts improved control in patient hands with FullSTEP®, a manageable, patient-titrated approach.1-3
Delivery devices designed to meet patients’ needs.
For use with NovoLog® FlexPen®, the #1 selling disposable, prefilled insulin device in the world.2 And introducing NovoPen Echo®, the first and only reusable insulin pen with a memory function and half-unit dosing.
NovoLog® is proven effective across a broad range of patients
NovoLog® (insulin aspart [rDNA origin] injection) is approved for pump use in children and adults.
Services for professionals
With a NovoMedLink™ ID you can order product samples, check formulary status and more.
a Formulary data are provided by Fingertip Formulary® and are current as of January 2015. Because formularies do change and many health plans offer more than one formulary, please check directly with the health plan to confirm coverage for individual patients. ⓒ 2015 Fingertip Formulary. All rights reserved.
b Managed care plans only. Does not include Medicaid and Medicare Part D. Intended as a guide. Lower acquisition costs alone do not necessarily reflect a cost advantage in the outcome of the condition treated because there are other variables that affect relative costs. Formulary status is subject to change. Multiple products within the same therapeutic class may be considered preferred and on the same tier.